Company Overview and News

79
PTC Therapeutics Surges On Positive Outcome From Rare Disease Study

2018-06-19 seekingalpha
PTC Therapeutic's stock soars on positive phase 1 results treating patients with a rare muscle wasting disease known as spinal muscular atrophy.
AVXS BIIB IONS NVS PTCT

13
AVXS / AveXis, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-06-11 sec.gov
SCHEDULE 13G Amendment No. 4 AVEXIS INC COMMON STOCK Cusip #05366U100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05366U100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #05366U100 Item 1: Reporting Person - Abigail P.
AVXS

13
AVXS / AveXis, Inc. / FMR LLC / Fidelity - null (Passive Investment)

2018-06-11 sec.gov
SCHEDULE 13G Amendment No. 4 AVEXIS INC COMMON STOCK Cusip #05366U100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05366U100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 0 Item 8: 0 Item 9: 0 Item 11: 0.000 % Item 12: HC Cusip #05366U100 Item 1: Reporting Person - Abigail P.
AVXS

13
AVXS / AveXis, Inc. null

2018-06-06 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,B]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
AVXS

13
AVXS / AveXis, Inc. 15-12B

2018-06-04 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

165
Crispr On Hold While Sangamo Accelerates

2018-06-04 seekingalpha
The gene editing group relying on Crispr was negatively impacted by the FDA hold on CTX001 last week.
NTLA AVXS CRSP ABEO ONCE RGNX VYGR BOLD EDIT CELG NVS BLUE ABEOW PFE

480
Biotechs: 4 Reasons And A Catalyst To Move Stocks Higher

2018-05-31 seekingalpha
The market is becoming more comfortable with risk as evidenced by the rise of the small cap index to a new all-time high.
ECYT AVXS GTHX LOXO ARNA ATRA IMMU BIIB CELG HRTX ADAP REGN AMGN GILD NBIX CRSP SRPT ARIA SUPN SNY CBIO JNJ MRTX NVS BGNE IRR CLSD PFE

102
U.S. IPO Weekly Recap: Payment IPOs Pay Off As 6 Deals Price Ahead Of Memorial Day

2018-05-27 seekingalpha
The average return for 2018 IPOs remained at about 23%. YTD IPOs have averaged a +13% first-day gain and +8% in the aftermarket. Currently, 68% of the year's 75 IPOs trade above issue. This past week, markets ticked slightly higher: Our IPO Index was up 0.3%, while the S&P 500 gained 0.5%. The VIX Volatility Index remained comfortably below 15.
ITRM SPRO AVXS GSKY SPOT MLNT EVOP SNAP IFRX

14
AVXS / AveXis, Inc. / Adage Capital Partners GP LLC - AVEXIS, INC. (Activist Investment)

2018-05-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

14
AVXS / AveXis, Inc. / Adage Capital Partners GP LLC - AVEXIS, INC. (Activist Investment)

2018-05-17 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
AVXS

99
Bluebird Bio: Gene Therapy Best In Class

2018-05-16 seekingalpha
The current quarterly cash burn remains modest leaving most of the group with enough capital to operate through 3 to 5 years.
NTLA AVXS BLUE CRSP ABEO ONCE RGNX VYGR BOLD EDIT BLUE ABEOW

13
AVXS / AveXis, Inc. null

2018-05-16 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A
AVXS

15
13
AVXS / AveXis, Inc. POS AM

2018-05-15 sec.gov
As filed with the Securities and Exchange Commission on May 15, 2018 Registration No. 333-216814
AVXS

16
AVXS / AveXis, Inc. S-8 POS

2018-05-15 sec.gov
As filed with the Securities and Exchange Commission on May 15, 2018 Registration No. 333-210592
AVXS

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

12h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 05366U100